Диссертация (1139975), страница 19
Текст из файла (страница 19)
– 2012. – Vol. 1. – P. e000703.149.Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrelbased on platelet function testing after percutaneous coronary intervention: theGRAVITAS randomized trial // JAMA. – 2011. – Vol. 305. – P. 1097–1105.150.Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened plateletreactivity despite dual-antiplatelet therapy in patients undergoing percutaneouscoronary intervention // Am J Cardiol. – 2009.
– Vol. 103. – P. 1339–1343.127151.Quadros AS, Welter DI, Camozzatto FO, et al. Identifying patients at risk forpremature discontinuation of thienopyridine after coronary stent implantation // AmJ Cardiol. – 2010. – Vol. 107. – P. 685–689.152.Ramsjo M, Aklillu E, Bohman L, et al.
CYP2C19 activity comparisonbetween Swedes and Koreans: effect of genotype, sex, oral contraceptive use, andsmoking // Eur J Clin Pharmacol. – 2010. – Vol. 66. – P. 871-877.153.Rangé G, Yayehd K, Belle L, Thuaire C, Richard P, Cazaux Pet al.Thrombotic and bleeding events after coronary stenting according to clopidogreland aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY) //Arch Cardiovasc Dis. – 2014.
– Vol. 107. – P. 225-235.154.Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P et al.Antiplatelet drug response status does not predict recurrent ischemic events instable cardiovascular patients: results of the Antiplatelet Drug Resistances andIschemic Events study // Circulation. – 2012. – Vol.
125. – P. 3201–3210.155.Reny JL, Combescure C, Daali Y, et al. Influence of the paraoxonase-1Q192Rgeneticvariantonclopidogrelresponsivenessandrecurrentcardiovascularevents: A systematic review and meta-analysis. // J ThrombosHaemostas. – 2012. – Vol. 10. – P. 1242-1251.156.Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SGet al. Prasugrel versus clopidogrel for acute coronary syndromes withoutrevascularization // N Engl J Med.
– 2012. – Vol. 367. – P. 1297–1309.157.Ruggeri Z.M. Platelets in atherothrombosis // Nature Med. – 2002. – Vol. 8.– P. 1227–1234.158.Santos et al. CYP2C19 and ABCB1 gene polymorphisms are differentlydistributed according to ethnicity in the Brazilian general population // BMCMedical Genetics. – 2011. – Vol.
12. – P. 1-7.128159.SatohT,HosokawaM.Structure,functionandregulationofcarboxylesterases // Chem Biol Interact. – 2006. – Vol. 162. – P. 195–211.160.Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biologicalactivity of the active metabolite of clopidogrel // Thromb Haemost. – 2000.
– Vol.84. – P. 891–896.161.Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebocontrolled clopidogrel trial // Circulation. – 2003. – Vol. 108. – P. 921–924.162.Scott SA, Sangkuhl K, Stein CM, et al; Clinical PharmacogeneticsImplementationConsortium.ClinicalPharmacogeneticsImplementationConsortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013update // Clin Pharmacol Ther. – 2013.
– Vol. 94. – P. 317-323.163.Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of plateletaggregation after clopidogrel with post discharge bleeding events: assessment bydifferent bleeding classifications // Eur Heart J. – 2010. – Vol. 31. – P. 227–235.164.Serebruany VL, Midei MG, Malinin AI, et al.
Absence of interactionbetween atorvastatin or other statin and clopidogrel: results from the interactionstudy // Arch Intern Med. – 2004. – Vol. 164. – P. 2051–2057.165.Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in plateletresponsiveness to clopidogrel among 544 individuals // J Am Coll Cardiol. – 2005.– Vol. 45. – P. 246–251.166.Sharom FJ. ABC multidrug transporters: structure, function and role inchemoresistance // Pharmacogenomics.
– 2008. – Vol. 9. – P. 105–127.167.Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochromeP450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogreltherapy // JAMA. – 2009. – Vol. 302. – P. 849–857.129168.Shuldiner AR, O'Connell JR, Gurbel PA et al. Influence of CYP2C19polymorphism on antiplatelet effects of clopidogrel and long-term recurrentischemic event occurrence // JAMA. – 2009.
– Vol. 302. – P. 849-858.169.Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogreltreatment assessed with point-of-care analysis and early drug-eluting stentthrombosis // J Am Coll Cardiol. – 2009. – Vol. 53. – P. 849–856.170.Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact ofcommon CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogreltherapy // J Thromb Haemost. – 2010. – Vol. 8. – P. 1685-1693.171.Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant,platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treatedpatients with coronary stent placement // Circulation.
– 2010. – Vol. 121. – P. 512–518172.Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosisafter coronary stenting // Eur Heart J. – 2011. – Vol. 32. – P. 1605-1613.173.Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel andbleeding in patients undergoing coronary stent placement // J Thromb Haemost. –2010. – Vol. 8.
– P. 250–256.174.Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronaryintervention // Eur Heart J. – 2009. – Vol. 30. – P. 916-922.175.Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and itsassociation with stent thrombosis and bleeding in clopidogrel-treated patients:initial evidence of a therapeutic window // J Am Coll Cardiol. – 2010. – Vol. 56. –P. 317–318.130176.Sibbing D, von Beckerath N, Morath T, et al.
Oral anticoagulation withcoumarin derivatives and antiplatelet effects of clopidogrel // Eur Heart J. – 2010. –Vol. 31. – P. 1205–1211.177.Sibbing D, von Beckerath O, Schomig A, et al. Impact of body mass indexon platelet aggregation after administration of a high loading dose of 600 mg ofclopidogrel before percutaneous coronary intervention // Am J Cardiol.
– 2007. –Vol. 100. – P. 203–205.178.Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelettreatment after percutaneous coronary intervention: the MADONNA study // Int JCardiol. – 2013. – Vol. 167. – P. 2018–2023.179.Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loadingdose on clinical outcome in patients undergoing percutaneous coronaryintervention: a systematic review and meta-analysis // Heart.
– 2011. – Vol. 97. – P.98–105.180.Siller-Matula JM, Jilma B, Schror K, et al. Effect of proton pump inhibitorson clinical outcome in patients treated with clopidogrel: a systematic review andmeta-analysis // J Thromb Haemost. – 2010. – Vol. 8. – P. 2624–2641.181.Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockersreduce the antiplatelet effect of clopidogrel // J Am Coll Cardiol.
– 2008. – Vol. 52.– P. 1557–1563.182.Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole andesomeprazole on platelet inhibition by clopidogrel // Am Heart J. – 2009. – Vol.157. – P. 148.e1–5.183.Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 genevariant causes ultrarapid drug metabolism relevant for the drug response to proton131pump inhibitors and antidepressants // Clin Pharmacol Ther. – 2006.
– Vol. 79. – P.103-113.184.Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants ofresponse to clopidogrel and cardiovascular events // N Engl J Med. – 2009. – Vol.360. – P. 363–375.185.SnoepJD,HovensMM,EikenboomJC,etal.Clopidogrelnonresponsiveness in patients undergoing percutaneous coronary intervention withstenting: a systematic review and meta-analysis // Am Heart J. – 2007. – Vol.
154. –P. 221-231.186.Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and riskof cardiovascular morbidity. An updated meta-analysis // Thromb Haemost. – 2010.– Vol. 103. – P. 841-848.187.Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoinhydroxylation deficiency in a Korean population and the inter phenotypicdifferences in diazepam pharmacokinetics // Clin Pharmacol Ther. – 1992. – Vol.52.
– P. 160–169.188.Spiewak M, Małek ŁA, Kostrzewa G et al. Influence of C3435T multidrugresistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis inpatients with acute coronary syndromes // Kardiol Pol. – 2009. – Vol. 67. – P. 827–834.189.Stec DE, Roman RJ, Flasch A, et al.
Functional polymorphism in humanCYP4F2 decreases 20-HETE production // Physiol Genomics. – 2007. – Vol. 30. –P. 74-81.190.Steg PG, James SK, et al. ESC Guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation // Eur HeartJ. – 2012. – Vol. 33. – P. 2569–2619.132191.Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinicaloutcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES):a prospective multicentre registry study // Lancet. – 2013.
– Vol. 382. – P. 614–623.192.Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizingenzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes //Pharmacogenetics. – 2000. – Vol. 10. – P. 187-216193.Sugimoto K, Uno T, Yamazaki H, et al. Limited frequency of theCYP2C19*17 allele and its minor role in a Japanese population // Br J ClinPharmacol.
– 2008. – Vol. 65. – P. 437-439.194.Tantry US, Bliden KP, Gurbel PA et al. What is the best measure ofthrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, orpost-treatment platelet aggregation? // Catheter Cardiovasc Interv. – 2005. – Vol.66. – P.
597–598.195.Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definitionof on treatment platelet reactivity to adenosine diphosphate associated withischemia and bleeding // J Am Coll Cardiol. – 2013. – Vol. 62. – P.2261–2273.196.Task Force Members, Montalescot G, Sechtem U, et al. ESC guidelines onthe management of stable coronary artery disease: the Task Force on themanagement of stable coronary artery disease of the European Society ofCardiology // Eur Heart J. – 2013. – Vol. 34.
– P. 2949–3003.197.Tatarunas V, Jankauskiene L, Kupstyte N, et al. The role of clinicalparameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms onplatelet reactivity during dual antiplatelet therapy // Blood Coagul Fibrinolysis. –2014. – Vol. 25. – P. 369-374.198.Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein onclopidogrel absorption // Clin Pharmacol Ther.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
